Clear Street analyst Kaveri Pohlman downgraded Ventyx Biosciences (VTYX) to Hold from Buy with a price target of $14, up from $11, after Eli Lilly (LLY) agreed to acquire Ventyx for $1.2B. Eli Lilly is a “logical” buyer given its focus on cardiometabolic health, immunology, and neuroscience, which aligns with Ventyx’s programs, the analyst tells investors in a research note. The firm added that Lilly currently lacks NLRP3 assets, suggesting Ventyx’s portfolio would complement its cardiometabolic and neurodegenerative franchises and could pair with existing therapies.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTYX:
- Eli Lilly to Acquire Ventyx Biosciences in Cash Deal
- Eli Lilly to acquire Ventyx Biosciences for $14.00 per share cash
- Eli Lilly to acquire Ventyx Biosciences for $14.00 per share in cash
- Midday Fly By: Warner Bros. urges holders to reject Paramount bid
- Unusually active option classes on open January 7th